Australia markets open in 5 hours 14 minutes

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.89-0.14 (-2.32%)
At close: 04:00PM EDT
5.66 -0.23 (-3.90%)
After hours: 05:16PM EDT

Seres Therapeutics, Inc.

200 Sidney Street
4th Floor
Cambridge, MA 02139
United States
617 945 9626
https://www.serestherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees333

Key executives

NameTitlePayExercisedYear born
Mr. Eric D. Shaff M.B.A.Pres, CEO & Director953.1kN/A1976
Mr. David A. Arkowitz M.B.A.Exec. VP, CFO & Head of Bus. Devel.603.33kN/A1961
Dr. Matthew R. Henn Ph.D.Exec. VP & Chief Scientific Officer591.78kN/A1975
Dr. David S. Ege Ph.D.Exec. VP & Chief Technology OfficerN/AN/A1974
Mr. Carlo Tanzi Ph.D.Investor Relations OfficerN/AN/AN/A
Mr. Thomas J. DesRosier Esq., J.D.Chief Legal Officer, Exec. VP & Sec.N/AN/A1955
Ms. Kristin AinsworthSr. VP of Corp. CommunicationsN/AN/AN/A
Mr. Jeff YorkVP of HRN/AN/AN/A
Ms. Paula A. Cloghessy SHRM-SCP, SPHRExec. VP & Chief People OfficerN/AN/A1972
Dr. Lisa von Moltke M.D.Exec. VP & Chief Medical OfficerN/AN/A1959
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Seres Therapeutics, Inc.’s ISS governance QualityScore as of 1 September 2022 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.